Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around $3.06 ...

US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact ...

Abbott is moving to acquire Exact Sciences, a molecular diagnostics company that specializes in the detection of early-stage ...

Exact SciencesEXAS stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced a ...

SEATTLE, July 31, 2024 /PRNewswire/ -- TwinStrand Biosciences today announced an agreement with Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, to ...

The shortened holiday week is here, and the futures are trading higher this morning. Most traders and investors are returning ...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded on the vision to push the boundaries of genetic medicine to address complex and devastating neurological diseases, announced the addition ...

TORONTO--(BUSINESS WIRE)--Lafarge Canada Inc. announces its investment in EXACT Technology Corporation, a fast-growing Toronto company that offers digital solutions for the concrete industry. The ...